For a six-month period, all airway options used for non-emergent patients undergoing thoracic surgery requiring onelung ventilation at a single institution were assessed after introduction of the VivaSight™ double-lumen endotracheal tube (VivaSight-DL), a novel double-lumen tube with an integrated camera. This device displays a continuous view of the position of the tube relative to the carina. A total of 72 patients had lung separation with the VivaSight-DL. Lung separation was achieved on first attempt without additional manipulation in 85% of cases. In only three cases (4%) was a fibreoptic bronchoscope required, in each instance to reposition the tube after intraoperative dislodgement. The VivaSight-DL represents a novel method of one-lung ventilation allowing rapid identification of intraoperative airway problems and reducing the need for fibreoptic bronchoscopy.
Introduction
Thoracic surgery often requires isolation of the operative lung or pleural space. One-lung ventilation (OLV) refers to the mechanical separation of ventilation between the two lungs, resulting in ventilation of only one lung. This technique is used either to facilitate exposure of the surgical field or to anatomically isolate one lung from a pathologic process of the other lung. The two most common methods of OLV for thoracic surgery are utilisation of a double-lumen tube (DLT) or a single-lumen endotracheal tube with a bronchial blocker [1] [2] [3] [4] [5] . Bronchial blockers are easily dislodged, require fibreoptic bronchoscope (FOB) placement, generally cost more than DLTs, and do not allow for suction and independent ventilation of the isolated lung except for limited continuous positive airway pressure 1, 6, 7 . In published surveys, the majority of thoracic anaesthetists choose DLTs due to the relative ease of placement and flexibility with deflation, reinflation, suctioning and differential ventilation [1] [2] [3] [4] [5] .
Correct placement of a DLT may be challenging. Initial malposition or subsequent dislodgement due to endobronchial cuff overinflation, surgical manipulation of the bronchus, or extension of the head and neck during or after patient positioning is not uncommon [8] [9] [10] . Visual confirmation of correct position with an FOB is generally regarded as the gold standard, as auscultation alone may be unreliable. However, use of an FOB requires training and can be timeconsuming, and its purchase and maintenance are expensive. Other techniques have been proposed for DLT placement confirmation such as fluoroscopy, ultrasound, rigid video stylets and inspiratory pressure difference determination between the lungs-none of which have gained widespread acceptance [11] [12] [13] [14] [15] .
Recently, a new single-use, left-sided, video-assisted DLT, the VivaSight™-DL (ETView Medical Ltd, Misgav, Israel), has become available. This disposable DLT has an integrated 2 mm camera similar to a smartphone camera and a light source embedded at the distal end of the tracheal lumen. A standard video monitor displays the camera view (Figure 1 ), enabling a continuous view of the trachea and carina during placement and throughout the entire surgical procedure. The VivaSight-DL has an 85 degree field-of-view CMOS (complementary metal-oxide semiconductor) image sensor with a resolution of 320 x 240 pixels 16 . The VivaSight-DL also has an integrated lumen to enable flushing with fluid or air to keep the camera lens clean. When correctly positioned, the video imaging device is focused on the carina, providing visual confirmation of the bronchial cuff in the left main bronchus. Unlike a conventional DLT, the VivaSight-DL provides continuous surveillance throughout the surgical procedure, allowing immediate identification of tube displacement and the possibility of avoiding the use of an FOB.
We introduced the VivaSight-DL into clinical thoracic anaesthesia practice in a single centre and audited the first six months of its use. The audit focused on the ease of endobronchial intubation, the quality of the camera view, whether additional use of an FOB was required, and the quality of one-lung anaesthesia as determined by the anaesthetist and surgeon. This audit of practice is unique due to the lack of exclusion criteria (and therefore real-world applicability), and the larger number of DLT placements studied in a single centre than any other video DLT report previously.
Materials and methods
We conducted an observational audit of clinical practice at a tertiary level teaching hospital in Queensland (The Prince Charles Hospital, Brisbane). Hospital ethics review board (Human Research and Ethics Committee) approval was obtained prior to audit initiation (HREC/14/QPCH/240) and individual patient consent was waived as the device use was listed on the Australian Register of Therapeutic Goods (ARTG#213888) for the intended purpose, and was already in use in our institution. We captured data for a period of six months from September 2014 to April 2015 on 72 adult patients undergoing thoracic procedures requiring OLV with the VivaSight-DL. During this time period, the conventional Mallinkrodt Broncho-Cath™ (Medtronic, Minneapolis, MN, USA) DLT remained available for any case deemed not appropriate for the VivaSight-DL. The management of anaesthesia care-including choice of DLT or bronchial blocker-monitoring, medications and other equipment was left to the discretion of the primary anaesthetist. Our aim was to identify the clinical real-world utility of the VivaSight-DL for thoracic anaesthetic practice as well as the overall satisfaction and utility of the VivaSight-DL from an anaesthetic and surgical perspective. Successful initial tube placement was defined as placing the VivaSight-DL into the left main bronchus on the first attempt resulting in clinical lung isolation at auscultation prior to surgical positioning and draping. If an intubation required patient or tube repositioning, use of an FOB, or a new tube, it was deemed an initial failure. We analysed the ability of the VivaSight-DL to attain OLV, optimal airway position, a continuous carinal view despite secretions and surgical movement of the airway, and to replace the conventional DLT in all patients. It was not possible to blind the surgeon as the screen and connections were clearly visible in the operating theatre.
All VivaSight-DLs were placed by anaesthetists with a special interest in cardiothoracic anaesthesia and with more than five years of experience, or advanced anaesthetic trainees under their direct guidance. The VivaSight-DL and conventional DLT were placed per standard practice. All data was recorded in the perioperative period in real time by a paper questionnaire completed by the primary anaesthetist. Seven-level qualitative rating scales were used to capture data. Data were analysed using SPSS 200.2. Pearson's chisquared test was used to compare frequencies. A P value <0.05 was considered statistically significant.
Results
We assessed six months of thoracic anaesthesia practice in which 100 elective thoracic surgical cases were performed (the audit was suspended temporarily in December 2014 for one month due to a screen malfunction of the VivaSight-DL). The VivaSight-DL was utilised in 72 cases in the audit period, a standard DLT was used in 27 cases, and in one case a bronchial blocker was used. The demographic data including age, height, weight, body mass index, gender and other factors are as shown in Table 1 . As the groups were not equivalent or randomised and DLT choice was at the discretion of the anaesthetist, the data from the VivaSight-DL patients and conventional DLT patients cannot be compared statistically. Conventional direct laryngoscopy was employed for much of the cohort, with videolaryngoscopy used in only six cases overall.
There were 11 anaesthetists providing anaesthesia during the audit, with most cases performed by five anaesthetists whose practice preferences dominated the results. Overall, the majority of anaesthetists elected to use the VivaSight-DL, except for two who did not use the VivaSight-DL during the audit period. Fifty-seven of the 72 (79%) VivaSight-DLs were successfully inserted by a trainee under direct guidance of the consultant.
The clear majority of cases were performed by two thoracic surgeons, while one case was done by a cardiac surgeon and two were unilateral whole lung lavages for alveolar proteinosis under the care of the anaesthetist only. The type of surgery is displayed in Table 2 . Approximately half the cohort had video-assisted thoracoscopic surgery (VATS) including pleurodesis, pleural biopsy, wedge and segmental resections. All cases were elective or semi-elective cases with no case presenting as a catastrophic airway emergency requiring lung isolation as a life-threatening priority.
Of the 72 cases in which the VivaSight-DL was used, 29 (40.3%) were left-sided surgery, 42 (58.3%) right and one (1.4%) bilateral thoracic surgery. The VivaSight-DL is only available as a left DLT, and in some thoracic surgical cases this means the VivaSight-DL cannot be used. During the audit period a total of seven conventional right-sided DLTs were used.
Anaesthetists using the conventional DLT were queried as to the reasons behind their preference (Table 3 ). Of the cases where the VivaSight-DL was not used, the most common indication given was teaching (nine cases). In these cases, the primary anaesthetist used an FOB along with a conventional DLT, bronchial blocker or right-sided tube to demonstrate to a trainee how to position the tube and troubleshoot intraoperatively using an FOB. In addition, there were case-specific factors which accounted for the use of ten conventional DLTs, including five where a right-sided tube was required for surgical reasons, two where a smaller size tube than available in the VivaSight-DL range was needed, and two when a 41Fr VivaSight-DL was not in stock. One patient had a predicted difficult airway, which warranted the use of FOB intubation as the primary plan of airway management.
First attempt success in placing the VivaSight-DL-defined as no initial need to change position of tube after inflating the bronchial cuff post-insertion-was achieved in 61 (85%) cases. Eleven cases (15%) required initial adjustment or replacement. Repositioning at the time of insertion with eventual success was possible in eight of these 11 cases and graded as easy. The remaining three cases were not easy to remedy. One patient was reintubated with the same VivaSight-DL allowing for an improved view, another was satisfactorily isolated only after turning to the lateral position, and the final patient had cuff rupture and a new VivaSight-DL was used. None of the VivaSight-DL cohort required the use of FOB assistance for initial positioning. The end goal of lung isolation for surgery scored well with the VivaSight-DL. In 85% of cases, the anaesthetist was happy with lung isolation, scoring 6 or more on a 7-point rating scale, while the surgeons gave the same score for more than 82% of cases (Figure 2A) .
The camera view was graded as adequate or better in more than 75% of cases. Flushing was required in 28 patients (39%) and most anaesthetists were not satisfied with the ability to improve the camera view even after flushing with air and/or saline ( Figure 2C ). Consequently, if repositioning was required in these patients, either a substandard view was tolerated or an FOB was used. After the initial successful isolation, data was captured for any subsequent repositioning required during surgery when VivaSight-DLs were used. This repositioning was necessary due to tube movement during patient positioning, or tube movement due to surgical traction and manipulation of the airway. Twenty-one VivaSight-DL cases (29%) required subsequent repositioning after initial success due to the aforementioned factors. Repositioning could be achieved using the camera in most instances, with only two of the twenty-one cases requiring the FOB. In both these cases the DLT camera view had deteriorated despite repeated flushing. Additionally an FOB was used in one other case to assist the location of a specific bronchus at the request of the surgeon.
In most cases the anaesthetist found the continuous view available with the VivaSight-DL helpful-with 73% giving a rating of five or more out of seven ( Figure 2B ).
Discussion
This prospective audit of practice assessed clinical use of the VivaSight-DL in a single centre. A total of 72 thoracic patients had lung isolation with the device allowing an in-depth analysis of its performance. Our conclusions can be divided into five main areas. Firstly, anaesthetic and surgical staff satisfaction with the performance of the VivaSight-DL to isolate the lungs without resorting to the FOB was high. Secondly, the continuous view allowed intraprocedural monitoring of DLT position, with benefits for intraoperative management. Thirdly, lubricant and airway secretions did affect camera performance, and often could not be resolved by flushing with saline or air. Fourth, due to a restricted range of VivaSight-DLs or specific surgical requirements, there were some patients who still required conventional DLT or bronchial blocker use. Lastly, the requirement for video capability requires an effectively functioning display screen, which we were not able to have for approximately one month due to monitor failure and replacement issues.
Anaesthetic staff satisfaction with the performance of the VivaSight-DL was high. Initial tube and subsequent continuous camera monitoring of the carina almost eliminated the need for use of the FOB. Initial placement with the VivaSight-DL never required an FOB. Repositioning of any tube displacement subsequently was accomplished without the FOB in the clear majority of cases-our rate of FOB use with the VivaSight-DL was just 4%. This compares well with the other VivaSight-DL cohorts with a range of 0% to 7%. This is in stark contrast to conventional DLT usage at our institution, which virtually always involves the FOB. Cost-effectiveness was beyond the scope of this study, but our institution incurs significant costs associated with FOB acquisition, decontamination, and repair, which were avoided using the VivaSight-DL. In addition, avoiding the use of the FOB allowed a significantly quicker tube placement, which could gain efficiencies for list turnover and patient flow.
One of the common causes of oxygen desaturation during OLV is DLT malposition. We believe the continuous visualisation of the carina by the VivaSight-DL allows the operator to quickly and simply assess tube position. If the position is unchanged the anaesthetist can quickly turn their focus onto other causes of hypoxia, and if the position has changed the continuous view allows rapid reversal of malposition. In our view this is the primary benefit of the VivaSight-DL in clinical practice.
Nevertheless, the VivaSight-DL has disadvantages. It has been recognised in other video DLT studies that the camera view can deteriorate over time due to secretions. Flushing and suctioning of the camera port via the specially designed suction tube does not always produce optimal results in cleaning the camera [17] [18] [19] [20] [21] . In our study, more than one-third of cases that required camera flushing did not clear the view optimally for the anaesthetist. We have found that not using lubricant on the tube, slow placement along the trachea to avoid picking up secretions on the camera, and pre-treatment of the camera lens with anti-fog improve the initial camera view considerably and allow for a longer period of optimal visualisation post-placement. The limited tube selection of VivaSight-DL means that it is not optimal for use in all patients. There are no right-sided VivaSight-DLs, and only 35, 37, 39 and 41 French sizes. This results in being unable to use this device in paediatric or proximal left main bronchus surgery. The monitor that the VivaSight-DL is linked with in Australia is also problematic. There is no battery backup and the monitor and its attachment system are easily damaged. There is a new monitor being produced for VivaSight-DL that will address some of these issues. However, it is not yet available in Australia.
There were other impacts noted with the use of the VivaSight-DL. A concern voiced from some consultant staff was that FOB skills would be compromised, especially given the rise of videolaryngoscopy. This could affect the skills of both registrar and consultant level anaesthetists over the longer term. The VivaSight-DL does offer other educational opportunities of trainee and consultant both observing intubation and positioning simultaneously. We believe the loss of FOB skills can be balanced by finding other opportunities, for example during formal bronchoscopy in intensive care and respiratory medicine.
Three previous studies have examined the VivaSight-DL in clinical practice. Schuepbach et al 22 conducted a randomised controlled trial on 40 patients scheduled for thoracic surgery to compare the clinical performance of the VivaSight-DL with that of a conventional DLT. The VivaSight-DL was positioned faster than a conventional DLT, tube displacement rates were similar, and the VivaSight-DL could be repositioned without use of the FOB. A multicentre trial 20 reported the successful use of the VivaSight-DL for endobronchial intubation in 151 consecutive patients scheduled for elective thoracic surgery in four different hospitals in Europe and Israel. Endobronchial intubation was successful in 98% of patients and lung isolation was successfully achieved in 99% of patients. The FOB was required to assist endobronchial tube placement in a small number of patients due to loss of video image quality due to secretions. Levy-Faber et al 18 conducted a prospective study of adult patients who underwent elective video-assisted thoracoscopic surgery for lung lobectomy. Compared with conventional DLT placement, the time for correct placement of a DLT using VivaSight-DL was reduced significantly and many more patients in the traditional DLT group required tube repositioning. The VivaSight-DL eliminated the need to re-verify the tube's position using the FOB once the patient had been turned to a lateral position.
The strengths of this audit are that it allowed a real-life utilisation of the VivaSight-DL video DLT in true clinical practice. In addition, this cohort has the largest number of patients included from a single centre. Limitations of this audit include the fact that it was not randomised or blinded to the anaesthetist or the surgeon, and the use of the specific type of DLT was chosen by the anaesthetist in charge of the case. This could have biased the results of the collected data due to specific anaesthetists' views on the VivaSight-DL related to conventional DLTs and therefore no direct comparison could be made for outcomes. Future studies could include a randomised clinical trial on the use of the VivaSight-DL versus conventional DLT for lung isolation, and a cost comparison analysis of this new technology with the use of conventional DLT and FOB together-considering the high cost of equipment and processing of FOBs and the possible cost savings in room turnover and list completion.
In summary, the use of a VivaSight-DL achieved successful surgical lung isolation and a low rate of FOB use. We would recommend its use to others in standard adult thoracic anaesthesia requiring lung isolation, as it offers anaesthetists the clinical advantage of a continuous view of the trachea, allowing monitoring of the position of the tube during initial insertion, subsequent patient repositioning and times of surgical manipulation. This allows rapid exclusion of malposition as a cause of intraoperative hypoxia or other airway-related events.
